Entrepreneur

Sanofi (SNY)/Regeneron’s Dupixent Meets Eczema Study Goal

Sanofi (SNY) and Regeneron (REGN)’s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five yea…

Leave a Reply

Your email address will not be published. Required fields are marked *